argenx SE
demonstrated favorable safety profile | argenx SE
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
13 of 21
Related slides by other companies
Chimerix
Investor Presentation
May 2023
safety a | Chimerix
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
jetBlue
Results
January 2021
| jetBlue
Theravance Biopharma
Investor Conference
November 2022
adverse events during randomized controlled phases | Theravance Biopharma
Other recent decks by argenx SE
See all presentations (28 decks)
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io